Accelerated suppression of primary Epstein-Barr virus infection in HIV-infected infants initiating lopinavir/ritonavir-based versus nevirapine-based combination antiretroviral therapy.
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 24550373.
- Also identified by DOI 10.1093/cid/ciu088 and PMC identifier 3982841.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
We compared primary Epstein-Barr virus (EBV) infection and suppression between Kenyan human immunodeficiency virus-infected infants starting nevirapine-based vs lopinavir/ritonavir-based antiretroviral regimens. Although the rate of EBV infection was similar between groups, infants receiving lopinavir/ritonavir suppressed EBV more rapidly. Our findings suggest that specific antiretrovirals may potentially impact the risk of future EBV-associated malignancies.
Medical subject headings
- Anti-HIV Agents
- Epstein-Barr Virus Infections
- HIV Infections
- Nevirapine
- Ritonavir